BOULDER, Colo., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that it is extending its collaborative agreement with global healthcare innovator, Novo Nordisk. As part of the agreement, which now extends into the end of 2025, Novo Nordisk will expand its use of the SomaScan^® proteomics platform in drug research and development. Novo Nordisk will also use SomaLogic’s SomaSignal^® tests for investigations into cardiometabolic and other diseases. This extension builds upon a previous agreement between the two companies, which was announced in 2021.

“SomaLogic has been very pleased with our partnership with Novo Nordisk which spans more than a decade,” said SomaLogic Chief Executive Officer Adam Taich. “We are proud that our SomaScan platform is being used in their research and development of new potential treatments for serious chronic diseases.”

Novo Nordisk previously partnered with SomaLogic to provide proteins of interest that expanded the SomaScan platform’s previous offering to its current industry-leading offering of more than 7,000 proteins. SomaLogic’s proprietary protein detection and analysis technology measures how proteins function and interact, supporting researchers in drug research and development, and biomarker identification efforts.

For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics technology. With this lineage comes a deep understanding of the needs that life science researchers have as they progress complex studies that demand both precision as well as skill and efficiency. The extension of this partnership with Novo Nordisk is the latest example of SomaLogic’s dedication to delivering the quality and quantity of biological insights to meet these needs - from bench to bedside.

About SomaLogic 
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

Forward Looking Statements Disclaimer 
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors.   Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. 

Media Contact   
Emilia Costales   
720-798-5054   
ecostales@somalogic.com

Investor Contact
Marissa Bych
investors@somalogic.com